Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Accured Expenses (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Change in Accured Expenses data on record, last reported at $2.5 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 2435.05% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $2.3 million, up 235.1%, while the annual FY2025 figure was $2.3 million, 235.1% up from the prior year.
  • Change in Accured Expenses reached $2.5 million in Q4 2025 per LCTX's latest filing, up from $271000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.5 million in Q4 2025 and bottomed at -$18.9 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is -$1.3 million, with a median of -$354000.0 recorded in 2025.
  • Peak YoY movement for Change in Accured Expenses: crashed 1733.66% in 2022, then soared 2435.05% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$1.0 million in 2021, then decreased by 9.51% to -$1.1 million in 2022, then soared by 202.83% to $1.2 million in 2023, then tumbled by 91.65% to $97000.0 in 2024, then skyrocketed by 2435.05% to $2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $2.5 million in Q4 2025, $271000.0 in Q3 2025, and -$354000.0 in Q2 2025.